On Demand Webinar | Overview | Payment Reimbursement and Managed Care
Save
Course | Basic | Payment Reimbursement and Managed Care
Save
On Demand Webinar | Intermediate | Payment Reimbursement and Managed Care
Save
Course | Basic | Payment Reimbursement and Managed Care
Save
Comment Letter | Payment Reimbursement and Managed Care

HFMA Comments on Most Favored Nation (MFN) Model Interim Final Rule

Comment Letter | Payment Reimbursement and Managed Care

HFMA Comments on Most Favored Nation (MFN) Model Interim Final Rule

In a comment letter to CMS regarding the Most Favored Nation (MFN) Model Interim Final Rule (IFC), published in the Federal Register on November 27, 2020, HFMA noted that its members request that CMS withdraw the MFN Model immediately and begin a process of working with impacted stakeholders to develop and propose a payment model pilot that will actually address this root cause of unchecked inflation in  drug costs – manufacturer prices. HFMA believes any model that addresses manufacturer prices should not just address separately payable Part B drugs, but all drugs covered by Medicare Parts A, B, C and D. The letter addresses key concerns of HFMA’s members in detail. Specific concerns about the MFN Model IFC addressed in the letter include its:

  • Adverse Impact to Medicare Beneficiaries and Providers Who Administer High Volumes of MFN Covered Drugs
  • Misappropriation of the Center for Medicare & Medicaid Innovation’s (CMMI’s) Writ Subvert Congress’s Authority and Implement a National Payment Cut for Selected Separately Payable Par B Drugs
  • Failure to Give Stakeholders an Adequate Notice and Opportunity to Comment as Required by the Administrative Procedures Act (APA)
  • Scope and Timing

Download the comment letter

Advertisements

Related Articles | Payment Reimbursement and Managed Care

Blog | Value-Based Payment

Medicare Advantage concepts come to Medicare fee-for-service with Geographic Direct Contracting Model

While the MA Stars Rating program is a bonus program where plans can earn additional revenue for achieving high scores, quality in the Geographic Direct Contracting program is treated more like a penalty, says HFMA's Chad Mulvany.

Blog | Coronavirus

CMS waiver for hospital-at-home designed to address COVID-19-driven capacity issues

While it’s been rumored that the Center for Medicare & Medicaid Innovation was working on a hospital-at-home model, this is a short-term waiver designed to address COVID-19-driven capacity issues, said HFMA’s Chad Mulvany.

Fact Sheet | Payment Reimbursement and Managed Care

CY 2021 Physician Fee Schedule Final Rule (and Interim Final Rules) Summary - Part I

HFMA presents a detailed summary of the CY 2021 physician fee schedule final rule and interim final rules, except the Quality Payment Program.

Fact Sheet | Payment Reimbursement and Managed Care

CY 2021 OPPS/ASC Final Rule Summary

HFMA presents a detailed summary of the CY 2021 OPPS and ASC payment system final rule, published by CMS.